Products - Chronic liver disease | Topic | NICE

Showing 7 products

Date | Title

New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
10 June 2026
Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
12 August 2026
Ex-situ machine perfusion devices for deceased donor liver transplants
Status:
In development
Programme:
Health technology evaluation
Expected publication date:
20 August 2026
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Status:
In development
Programme:
NICE guideline
Expected publication date:
2 December 2026
Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
6 January 2027
Seladelpar for previously treated primary biliary cholangitis [ID6429]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Norucholic acid for treating primary sclerosing cholangitis [ID6583]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC